Field Trip Health Ltd.

<!-- Name:DistributionId Value:8793689 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value: --> <!-- Name:CustomerId Value:1262670 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:150a0924-2718-4193-bef6-649624065f26 --> TORONTO, March 22,... Read More...

<!-- Name:DistributionId Value:8788902 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value: --> <!-- Name:CustomerId Value:1262670 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:97033991-d011-46e0-917f-9b83e290356e --> TORONTO, March 15,... Read More...

<!-- Name:DistributionId Value:8742185 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value: --> <!-- Name:CustomerId Value:1262670 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:36d88576-aa96-435c-82a4-623095aabbff --> TORONTO, Feb. 03, ... Read More...

TORONTO, Jan. 12, 2023 -- Field Trip Health & Wellness Ltd. (TSX-V: FTHW) ("Field Trip" or the “Company”), a global leader in the delivery of psychedelic therapies, today launched Field Trip Online Therapy, a unique approach to psychotherapy that leverages contemporary talk therapy, integrative wellness tools and insights derived from... Read More...

TORONTO, Aug. 16, 2022 -- Field Trip Health & Wellness Ltd. (the "Company" of “Field Trip”), a global leader in the development and delivery of psychedelic therapies, is pleased to announce that its common shares (the "Shares") will commence trading on the TSX Venture Exchange (“TSXV”) under the ticker symbol “FTHW” at the opening of ... Read More...

TORONTO, Aug. 15, 2022 -- Field Trip Health & Wellness Ltd. (the "Company") is pleased to announce that it has filed a listing application in connection with the previously announced intention to list its common shares (the "Shares") on the TSX Venture Exchange (“TSXV”). It is anticipated that the Shares will commence trading on the T... Read More...

- First Dosings completed in Australia- Provides Update on Pending Spin-Out and Renaming to Reunion Neurosciences- Announces 5:1 Share Consolidation Ratio TORONTO, July 21, 2022 -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip" or the “Company”), a global leader in the development and delivery of psychedelic thera... Read More...

- Closing of arrangement subject to regulatory approvals, including conditional listing approval by the TSX Venture Exchange.- Closing of the arrangement expected to occur in August.- Also announces closing of subscription receipt offering. TORONTO, June 29, 2022 -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip" ... Read More...

TORONTO, June 27, 2022 -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip" or "Corporation"), a global leader in the development and delivery of psychedelic therapies, today announced that on June 27, 2022, its shareholders approved both the Arrangement Resolution, the Concurrent Financing Resolution and the SpinCo ... Read More...

TORONTO, June 14, 2022 -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) (the "Company" or "Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it has agreed to increase its participation in the concurrent financing, in support of, and in connection with, the spin-out of ... Read More...

TORONTO, April 29, 2022 -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip’s management team will participate in two investor conferences in May 2022. 2022 Bloom Burton & Co. Healthcare Investor Conferenc... Read More...

TORONTO, April 05, 2022 -- Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, today announced that the U.S. Patent and Trademark Office (“USPTO”) has granted the Company a patent for claims related to FT-104 (informally known as “Isoprocin Glutarate”),... Read More...

Field Trip Health currently has clinics operating in eight major U.S. cities, making it the largest provider of psychedelic-assisted therapies in North America. With this partnership, Field Trip Health patients will have access to services beyond psychedelic treatments and can now access a holistic offering of mental health treatments th... Read More...

TORONTO, Dec. 14, 2021 -- Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, today announced the launch of its Site Management Organization Services (“SMO Services”). The SMO Services will enable companies and researchers developing psychedelic therapi... Read More...

TORONTO, Oct. 19, 2021 -- Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today the opening of their Seattle clinic, their sixth in the United States, along with the recent opening of a location in Fredericton, NB, and the imminent opening... Read More...

TORONTO, Sept. 24, 2021 -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; Nasdaq: FTRP) ("Field Trip"), today announced the voting results from its Annual General and Special Meeting of Shareholders held on Friday, September 24, 2021. A total of 59.09% of the issued and outstanding common shares of the Corporation were represented either in ... Read More...

TORONTO, Sept. 10, 2021 -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; Nasdaq: FTRP) ("Field Trip"), a leader in the development and delivery of psychedelic therapies, today announced it will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit, the M... Read More...

TORONTO, Sept. 09, 2021 -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; NASDAQ: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today the lead indications for FT-104, its novel psychedelic compound in development, will be Treatment Resistant Depression (TRD) and Postpartum Depressio... Read More...

Self-discovery and inner healing Therapy using truffles can help people break free from routine thinking patterns. Years of suppressed emotions and memories can surface and distorted beliefs can be reframed. These experiences can lead to deep self-discovery and inner healing. Psychedelic experiences can also contribute to the psychothera... Read More...

The KAP Co-op program gives eligible therapists the ability to provide ketamine-assisted psychotherapy (KAP) to their patients at Field Trip Health Centers utilizing Field Trip’s medical teams for screening, prescribing and administration of ketamine.Training programs will provide both didactic and experiential training to therapists and ... Read More...